DexCom (DXCM) Projected to Announce Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is anticipated to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.6750 per share and revenue of $1.33 billion for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the prior year, the business posted $0.48 earnings per share. The business’s quarterly revenue was up 13.1% on a year-over-year basis. On average, analysts expect DexCom to post $2.64 EPS for the current fiscal year and $3.08 EPS for the next fiscal year.

DexCom Trading Down 0.0%

Shares of NASDAQ DXCM opened at $78.56 on Wednesday. DexCom has a one year low of $54.11 and a one year high of $92.59. The firm’s 50 day simple moving average is $86.40 and its two-hundred day simple moving average is $74.48.

Insiders Place Their Bets

In related news, EVP Jereme M. Sylvain sold 3,638 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the sale, the executive vice president directly owned 146,828 shares in the company, valued at $12,226,367.56. This represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the sale, the executive vice president directly owned 98,185 shares in the company, valued at approximately $8,392,853.80. This trade represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 24,257 shares of company stock worth $2,049,173. 0.28% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent research reports. Royal Bank Of Canada restated an “outperform” rating and issued a $105.00 price objective (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Mizuho set a $100.00 price objective on shares of DexCom in a research note on Tuesday, October 13th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. TD Cowen reaffirmed a “buy” rating and set a $95.00 target price on shares of DexCom in a report on Friday, September 18th. Finally, UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $92.43.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.